[1] WHO. WHO Coronavirus (COVID-19) Dashboard [DB/OL].(2021-08-18)[2021-08-18]. https://covid19.who.int. [2] WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [DB/OL].(2015-07-24) [2021-08-18]. https://www.who.int/publications/m/item/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003. [3] WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 27 July 2020[DB/OL].(2020-07-27)[2021-11-11]. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-27-july-2020. [4] YU DX, CHEN Q, ZHANG LL, et al.Recombinant human interferon α-2b spray for prevention of respiratory virus infections such as SARS[J]. Chinese Journal of Experimental and Clinical Virology, 2005, 19(3): 216-219. [5] WILDE AH, RAJ VS, OUDSHOORN D, et al.MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment[J]. Journal of General Virology, 2013, 94(8): 1749-1760. [6] SALEKI K, YARIBASH S, BANAZADEH M, et al.Interferon therapy in patients with SARS, MERS, and COVID-19: a systematic review and meta-analysis of clinical studies[J]. European Journal of Pharmacology, 2021, 906: 174248. [7] GAO H, ZHANG LL, WEI Q, et al Recombinant human interferon α 2b nasal spray for prevention and treatment of SARS-CoV infection in Ganges River monkeys[J]. Chinese Journal of Experimental and Clinical Virology 2005, 19(3): 207-210. [8] MANTLO E, BUKREYEVA N, MARUYAMA J, et al.Antiviral activities of type I interferons to SARS-CoV-2 infection[J]. Antiviral Research, 2020, 179: 104811. [9] LOKUGAMAGE K G, HAGE A, VRIES M D, et al.Type I interferon susceptibility distinguishes SARSCoV-2 from SARS-CoV[J]. J Virol, 2020, 94(23): e01410-01420. [10] ZHOU Q, CHEN V, SHANNON C P, et al.Interferon-α2b treatment for COVID-19[J]. Frontiers in Immunology, 2020, 11: 1061. [11] JIONG Y, XUAN L, LING T, et al.Interferon-α-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019[J]. British Journal of Clinical Pharmacology, 2021, 87(12): 4737-4746 [12] National Health Commission, PRC. COVID-19 diagnosis and treatment protocol (trial eighth revised edition)[J]. Chin J Clin Infect Dis, 2021,14(2): 81-88. [13] WANG Y, ZHANG D, DU G, et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395(10236): 1569-1578. [14] SCAGNOLARI C, ANTONELLI G.Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C[J]. Expert Opinion on Biological Therapy, 2013, 13(5): 693-711. [15] YANG E, LI MMH.All about the rna: interferon-stimulated genes that interfere with viral RNA processes[J]. Front. Immunol, 2020, 11: 605024. [16] SAMUEL CE.Antiviral actions of interferons[J]. Clin Microbiol Rev, 2001, 14(4): 778. [17] MANGAN NE, FUNG KY.Type I interferons in regulation of mucosal immunity[J]. Immunology and Cell Biology, 2012, 90(5): 510-519. [18] KONNO Y, KIMURA I, URIU K, et al.SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant[J]. Cell Reports, 2020, 32(12): 108185. [19] CHU H, CHAN JF, WANG Y, et al.Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the Pathogenesis of COVID-19[J]. Clinical Infectious Diseases, 2020, 71(6): 1400-1409. [20] BASTARD P, ROSEN LB, ZhANG Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19[J]. Science, 2020, 370(6515): 4585. [21] HADJADJ J, YATIM N, BARNABEI L, et al.Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients[J]. Science, 2020, 369(6504): 718-724. [22] ZHANG Q, BASTARD P, LIU Z, et al.Inborn errors of type I IFN immunity in patients with life-threatening. COVID-19[J]. Science, 2020, 370(6515): 422. [23] MENG Z, WANG T, LI C, et al.The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area[J]. Curr Top Med Chem, 2021, 21(10): 920-927. [24] ZHOU Q, CHEN V, SHANNON CP, et al.Interferon-α2b Treatment for COVID-19[J]. Frontiers in Immunology, 2020, 11: 1061. [25] PDM A, RJMB A, VJ TA, et al.Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial - Science Direct[J]. Lancet Respir Med, 2021, 9(2): 196-206. [26] HAO SR, YAN R, ZHANG SY, et al.Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study[J]. Journal of Zhejiang University Science B, 2020, 21(8): 628-636. [27] FU WA, LIU YA, XIA LA, et al.A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19- ScienceDirect[J]. Eclinical Medicine, 2020, 25:100478. [28] PAN H, PETO R, HENAO-RESTREPO AM, et al.Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results[J]. New England Journal of Medicine, 2021, 384(6): 497-511 [29] HUNG IF, LUNG KC, TSO EY, et al.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial[J]. Lancet (London, England), 2020, 10238(395): 1695-1704. [30] WANG N, ZHAN Y, ZHU L, et al.Retrospective multicenter cohort study shows that early interferon therapy is associated with favorable clinical responses in COVID-19 patients[J]. Cell Host & Microbe, 2020, 28(3): 455-464. |